Teva to pay $512 million to settle claims of delayed generic Provigil

(Reuters) - Teva Pharmaceutical Industries Ltd has agreed to pay $512 million to settle a class action claiming that Cephalon Inc, which Teva bought in 2011, used anticompetitive settlements to delay generic versions of its wakefulness drug Provigil.

Source: Reuters: Health - April 20, 2015 Category: Consumer Health News Tags: healthNews Source Type: news